Financial Times – 4/11/13

Michael Kastner, principal at Halyard Asset Management, said the growth potential for biotechs remained promising but the sector had become expensive.

“In terms of investment stories, it’s good for investors but prices have run up so much that I think we are seeing some aggressive traders pushing it around.”

Asia and Europe feel the pain as US tech rout spreads